Peter van der Ark

716 total citations
20 papers, 522 citations indexed

About

Peter van der Ark is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Endocrine and Autonomic Systems. According to data from OpenAlex, Peter van der Ark has authored 20 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cognitive Neuroscience, 7 papers in Experimental and Cognitive Psychology and 6 papers in Endocrine and Autonomic Systems. Recurrent topics in Peter van der Ark's work include Sleep and related disorders (7 papers), Tryptophan and brain disorders (6 papers) and Sleep and Wakefulness Research (6 papers). Peter van der Ark is often cited by papers focused on Sleep and related disorders (7 papers), Tryptophan and brain disorders (6 papers) and Sleep and Wakefulness Research (6 papers). Peter van der Ark collaborates with scholars based in Belgium, United States and Netherlands. Peter van der Ark's co-authors include Wayne C. Drevets, Luc Van Nueten, Peter de Boer, Joop van Gerven, Rob Zuiker, Gabriël E. Jacobs, R. Luthringer, Mark E. Schmidt, Justine Kent and Iva Kezic and has published in prestigious journals such as Neuropsychopharmacology, Molecular Psychiatry and SLEEP.

In The Last Decade

Peter van der Ark

20 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter van der Ark Belgium	12	201	187	177	157	103	20	522
Roxanne Sterniczuk Canada	11	227 1.1×	136 0.7×	55 0.3×	275 1.8×	72 0.7×	15	696
Kara L. Stuhr United States	11	199 1.0×	107 0.6×	618 3.5×	179 1.1×	47 0.5×	12	812
Makoto Okuya Japan	12	107 0.5×	130 0.7×	133 0.8×	60 0.4×	79 0.8×	32	596
M Uhr Germany	13	179 0.9×	161 0.9×	37 0.2×	290 1.8×	122 1.2×	17	771
Analía M. Furio Argentina	9	273 1.4×	230 1.2×	43 0.2×	483 3.1×	123 1.2×	10	702
Nagendra M. Singh India	9	112 0.6×	79 0.4×	123 0.7×	46 0.3×	79 0.8×	11	370
Ligia Westrich United States	10	99 0.5×	74 0.4×	211 1.2×	28 0.2×	90 0.9×	11	439
Mette Haahr Denmark	12	135 0.7×	46 0.2×	91 0.5×	51 0.3×	58 0.6×	19	478
Kumar Budur United States	12	139 0.7×	106 0.6×	51 0.3×	50 0.3×	78 0.8×	26	591
Martha López-Canul Canada	11	150 0.7×	47 0.3×	282 1.6×	185 1.2×	104 1.0×	19	783

Countries citing papers authored by Peter van der Ark

Since Specialization

Citations

This map shows the geographic impact of Peter van der Ark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter van der Ark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter van der Ark more than expected).

Fields of papers citing papers by Peter van der Ark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter van der Ark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter van der Ark. The network helps show where Peter van der Ark may publish in the future.

Co-authorship network of co-authors of Peter van der Ark

This figure shows the co-authorship network connecting the top 25 collaborators of Peter van der Ark. A scholar is included among the top collaborators of Peter van der Ark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter van der Ark. Peter van der Ark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Mark E., Iva Kezic, Vanina Popova, et al.. (2024). Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. 49(9). 1437–1447. 21 indexed citations

Kezic, Iva, Peter van der Ark, Mila Etropolski, et al.. (2024). Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Molecular Psychiatry. 30(6). 2427–2435. 6 indexed citations

Boer, Peter de, Peter van der Ark, Heike Beneš, et al.. (2023). Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Translational Psychiatry. 13(1). 266–266. 36 indexed citations

Buchhalter, Jeffrey, Caroline Neuray, Jocelyn Y. Cheng, et al.. (2022). EEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper. Epilepsy Research. 187. 107028–107028. 8 indexed citations

Tesseur, Ina, Darrel J. Pemberton, Peter van der Ark, et al.. (2022). Concordance of Alzheimer’s Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer s Disease. 91(1). 305–319. 1 indexed citations

Zuiker, Rob, Gabriël E. Jacobs, Iva Kezic, et al.. (2021). 341 Acute effects of seltorexant, a selective orexin-2 antagonist (JNJ- 42847922), on driving after bedtime administration. SLEEP. 44(Supplement_2). A136–A136. 1 indexed citations

Schmidt, Mark E., Michael R. Liebowitz, Murray B. Stein, et al.. (2020). The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 46(5). 1004–1010. 67 indexed citations

Boer, Peter de, Rob Zuiker, R. Luthringer, et al.. (2019). The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Translational Psychiatry. 9(1). 216–216. 65 indexed citations

Jacobs, Gabriël E., Peter de Boer, Justine Kent, et al.. (2019). The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of Psychopharmacology. 33(2). 202–209. 55 indexed citations

10.

Leinonen, Ville, Darrel J. Pemberton, Peter van der Ark, et al.. (2019). P1‐257: LONGITUDINAL COMPARISON OF CSF BIOMARKERS OF NEURODEGENERATION IN PATIENTS WITH PROBABLE IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH). Alzheimer s & Dementia. 15(7S_Part_6). 1 indexed citations

11.

Boer, Peter de, Wayne C. Drevets, Hany Rofael, et al.. (2018). A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of Psychopharmacology. 32(6). 668–677. 45 indexed citations

12.

Ark, Peter van der, Georg Golor, Luc Van Nueten, Partha Nandy, & Peter de Boer. (2018). Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. Journal of Psychopharmacology. 32(12). 1330–1340. 16 indexed citations

13.

Morrison, Randall L., Maggie Fedgchin, Jaskaran Singh, et al.. (2018). Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology. 235(4). 1107–1119. 57 indexed citations

14.

Postnov, Andrey, Mark E. Schmidt, Darrel J. Pemberton, et al.. (2018). Fatty Acid Amide Hydrolase Inhibition by JNJ‐42165279: A Multiple‐Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers. Clinical and Translational Science. 11(4). 397–404. 38 indexed citations

15.

Loo, Aurora J.A.E. van de, Johan Garssen, Rob Zuiker, et al.. (2017). The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study. Psychopharmacology. 234(21). 3175–3183. 22 indexed citations

16.

Brooks, Stephen N., Justine Kent, Gabriël E. Jacobs, et al.. (2016). The orexin-2 antagonist JNJ-42847922 (MIN-202) improves sleep in patients with major depressive disorder (MDD) suffering from comorbid insomnia. European Neuropsychopharmacology. 26. S408–S409. 1 indexed citations

17.

Bailey, Jayne, Alison Diaper, Peter van der Ark, et al.. (2011). Preliminary evidence of anxiolytic effects of the CRF₁ receptor antagonist R317573 in the 7.5% CO₂ proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology. 25(9). 1199–1206. 45 indexed citations

18.

Schmidt, Mark E., Randolph D. Andrews, Peter van der Ark, et al.. (2009). Dose-dependent effects of the CRF1 receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology. 208(1). 109–119. 25 indexed citations

19.

Bailey, Jayne, A. Papadopoulos, Alison Diaper, et al.. (2008). P.4.c.003 Preliminary evidence of efficacy of a CRF1 receptor antagonist in the 7.5% CO2 model of anxiety. European Neuropsychopharmacology. 18. S494–S494. 1 indexed citations

20.

Slappendel, R., et al.. (2006). Patients with and without rheumatoid arthritis benefit equally from preoperative epoetin-α treatment. Acta Orthopaedica. 77(4). 677–683. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact